Shanghai Zhuanma Biotechnology Co., Ltd. has recently declared the triumphant conclusion of its Pre-A round financing, garnering tens of millions of yuan. This funding round witnessed joint investment from Zeyue Venture Capital, Yifeng Zhuohua Fund, and Mifang Health Fund. The capital raised will be predominantly channeled into advancing the Investigational New Drug (IIT) research and clinical trial preparations for the company's flagship pipeline, as well as expediting the development of the in vivo gene therapy platform.

Established in July 2023, Zhuanma Biotechnology is dedicated to translating its proprietary ultra-compact gene editor, alphaCas®, into in vivo gene therapy medications. As the inaugural complete CRISPR/Cas gene family independently identified by Chinese scientists within China, alphaCas® boasts substantial benefits over the prevailing CRISPR/Cas9 system.

At present, Zhuanma Biotechnology has set up two technology platforms for in vivo gene editing therapy and has developed multiple therapeutic pipelines that are on the verge of entering the IIT research phase. The investors express confidence in the growth prospects of Zhuanma Biotechnology, convinced that it holds the potential to realize the objective of 'one-time treatment, lifelong cure,' thereby offering hope to a broader spectrum of patients.